TY - JOUR
T1 - Translocator protein (18 kDa)
T2 - new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function
AU - Papadopoulos, Vassilios
AU - Baraldi, Mario
AU - Guilarte, Tomás R.
AU - Knudsen, Thomas B.
AU - Lacapère, Jean Jacques
AU - Lindemann, Peter
AU - Norenberg, Michael D.
AU - Nutt, David
AU - Weizman, Abraham
AU - Zhang, Ming Rong
AU - Gavish, Moshe
N1 - Funding Information:
We thank Elspeth Bruford (HGNC) and HGNC for assistance and guidance with the proposed new nomenclature, and Leo Veenman (Bruce Rappaport Family Institute for Research in the Medical Sciences) and Gary Weisinger (Tel Aviv University Sourasky Medical Center) for helpful comments. We apologize to many of our colleagues whose work is not cited or is cited indirectly owing to space limitations. The work of the ‘working group for renaming the PBR’ was supported by Novartis Pharmaceuticals. We thank various government agencies, foundations and private sponsors for supporting our work over the years.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2006/8
Y1 - 2006/8
N2 - The peripheral-type benzodiazepine receptor or recognition site (PBR) is a widely distributed transmembrane protein that is located mainly in the outer mitochondrial membrane. The PBR binds to high-affinity drug ligands and cholesterol. Many functions are associated directly or indirectly with the PBR, including the regulation of cholesterol transport and the synthesis of steroid hormones, porphyrin transport and heme synthesis, apoptosis, cell proliferation, anion transport, regulation of mitochondrial functions and immunomodulation. Based on these functions, there are many potential clinical applications of PBR modulation, such as in oncologic, endocrine, neuropsychiatric and neurodegenerative diseases. Although 'PBR' is a widely used and accepted name in the scientific community, recent data regarding the structure and molecular function of this protein increasingly support renaming it to represent more accurately its subcellular role (or roles) and putative tissue-specific function (or functions). Translocator protein (18 kDa) is proposed as a new name, regardless of the subcellular localization of the protein.
AB - The peripheral-type benzodiazepine receptor or recognition site (PBR) is a widely distributed transmembrane protein that is located mainly in the outer mitochondrial membrane. The PBR binds to high-affinity drug ligands and cholesterol. Many functions are associated directly or indirectly with the PBR, including the regulation of cholesterol transport and the synthesis of steroid hormones, porphyrin transport and heme synthesis, apoptosis, cell proliferation, anion transport, regulation of mitochondrial functions and immunomodulation. Based on these functions, there are many potential clinical applications of PBR modulation, such as in oncologic, endocrine, neuropsychiatric and neurodegenerative diseases. Although 'PBR' is a widely used and accepted name in the scientific community, recent data regarding the structure and molecular function of this protein increasingly support renaming it to represent more accurately its subcellular role (or roles) and putative tissue-specific function (or functions). Translocator protein (18 kDa) is proposed as a new name, regardless of the subcellular localization of the protein.
UR - http://www.scopus.com/inward/record.url?scp=33746035655&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746035655&partnerID=8YFLogxK
U2 - 10.1016/j.tips.2006.06.005
DO - 10.1016/j.tips.2006.06.005
M3 - Article
C2 - 16822554
AN - SCOPUS:33746035655
VL - 27
SP - 402
EP - 409
JO - Trends in Pharmacological Sciences
JF - Trends in Pharmacological Sciences
SN - 0165-6147
IS - 8
ER -